Cargando…
Diabetes‐induced upregulation of kallistatin levels exacerbates diabetic nephropathy via RAS activation
Kallistatin is an inhibitor of tissue kallikrein and also inhibits the Wnt pathway. Its role in diabetic nephropathy (DN) is uncertain. Here we reported that serum kallistatin levels were significantly increased in diabetic patients with DN compared to those in diabetic patients without DN and healt...
Autores principales: | Yang, Yanhui, He, Xuemin, Cheng, Rui, Chen, Qian, Shan, Chunyan, Chen, Liming, Ma, Jian‐xing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302980/ https://www.ncbi.nlm.nih.gov/pubmed/32352602 http://dx.doi.org/10.1096/fj.201903149R |
Ejemplares similares
-
Increased serum kallistatin levels in type 1 diabetes patients with vascular complications
por: Jenkins, Alicia J, et al.
Publicado: (2010) -
Nicotine exacerbates diabetic nephropathy through upregulation of Grem1 expression
por: Chen, Jianning, et al.
Publicado: (2023) -
Inhibition of RAS in diabetic nephropathy
por: Yacoub, Rabi, et al.
Publicado: (2015) -
Pathogenic Role of Diabetes-Induced Overexpression of Kallistatin in Corneal Wound Healing Deficiency Through Inhibition of Canonical Wnt Signaling
por: Liang, Wentao, et al.
Publicado: (2022) -
Kallistatin - the score beats the marker
por: Draikiwicz, Steven, et al.
Publicado: (2013)